Articles

Beth Faiman argues that patient support services are integral in her role as a nurse because they aid in getting patients the treatments they need, promote adherence, and provide patient education. Read More ›

Researchers presented updated results of the randomized phase 3 ELOQUENT-2 study that evaluated the anti-SLAM7 monoclonal antibody elotuzumab plus lenalidomide/dexamethasone versus lenalidomide/dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (RRMM). Read More ›

This study analyzed data from the longitudinal CoMMpass trial led by the Multiple Myeloma Research Foundation to determine the degree to which the International Staging System (ISS) stage was associated with disease and symptom burden in patients with newly diagnosed multiple myeloma (MM). Read More ›

Researchers reported long-term follow-up results of the HOVON-65/GMMG-HD4 trial that evaluated survival outcomes with bortezomib-based induction and maintenance regimens followed by high-dose melphalan and autologous stem-cell transplantation in transplant-eligible patients with newly diagnosed multiple myeloma (MM) compared with the standard regimen. The impact of the bortezomib-based regimen on survival in the high-risk cytogenetic and renally impaired subset of patients was also reported. Read More ›

To further optimize therapy, this study identified subgroups that benefited least from bortezomib/melphalan/prednisone followed by lenalidomide/dexamethasone regimen in newly diagnosed patients aged 65 to 80 years with multiple myeloma (MM) included in the GEM2010 trial. Read More ›

Ali McBride provides some ideas to promoting oral adherence. Read More ›

R. Donald Harvey offers suggestions for what might help with greater medication adherence. Read More ›

Ali McBride offers suggestions and ways to help patients with out-of-pocket expenses. Read More ›

Beth Faiman talks about the excitement of new medications but the challenge of getting to a standard of care that includes these new drugs. Read More ›

Beth Faiman talks about the excitement of new medications but the challenge of getting to a standard of care that includes these new drugs. Read More ›